A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) (BLAZE-5)

J2X-MC-PYAJ -

The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse.

Trial Summary

Age Range
≥12 years
Conditions the trial is for
COVID-19
What the trial is testing?
Bamlanivimab
Could I receive a Placebo?
No
Enrollment Goal
109
Trial Dates
Feb 1, 2021 - Jun 22, 2021
How long will I be in the trial?
Your participation could last about 3 months and may include up to 2 visits to the study center.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have mild to moderate symptoms of COVID-19

  • Participants must test positive for COVID-19 within 10 days of first symptom(s)

  • Participants must be at high risk for progressing to severe COVID-19 and/or needing hospitalization

Participants Must Not:

  • Participants must not be in the hospital

  • Participants must not be very overweight

  • Participants must not need a machine to help them breathe (ventilator)

  • Participants must not have a serious medical condition or infection other than COVID-19

  • Participants must not have received SARS-CoV-2 vaccine or plasma from a patient who has recovered from COVID-19 (convalescent plasma)

  • Participants must not be pregnant or breastfeeding

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.